JPWO2021257353A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021257353A5 JPWO2021257353A5 JP2022577145A JP2022577145A JPWO2021257353A5 JP WO2021257353 A5 JPWO2021257353 A5 JP WO2021257353A5 JP 2022577145 A JP2022577145 A JP 2022577145A JP 2022577145 A JP2022577145 A JP 2022577145A JP WO2021257353 A5 JPWO2021257353 A5 JP WO2021257353A5
- Authority
- JP
- Japan
- Prior art keywords
- pharma
- hydrogen
- acceptable salt
- compound
- ceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063039873P | 2020-06-16 | 2020-06-16 | |
| US63/039,873 | 2020-06-16 | ||
| PCT/US2021/036706 WO2021257353A1 (en) | 2020-06-16 | 2021-06-10 | Plasma kallikrein inhibitors |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2023531411A JP2023531411A (ja) | 2023-07-24 |
| JPWO2021257353A5 true JPWO2021257353A5 (https=) | 2024-05-08 |
| JP2023531411A5 JP2023531411A5 (https=) | 2024-05-08 |
| JP7776453B2 JP7776453B2 (ja) | 2025-11-26 |
Family
ID=79268261
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022577145A Active JP7776453B2 (ja) | 2020-06-16 | 2021-06-10 | 血漿カリクレイン阻害剤 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US12459927B2 (https=) |
| EP (1) | EP4164634A4 (https=) |
| JP (1) | JP7776453B2 (https=) |
| KR (1) | KR102931248B1 (https=) |
| CN (1) | CN115989224B (https=) |
| AU (1) | AU2021292449A1 (https=) |
| BR (1) | BR112022025528A2 (https=) |
| CA (1) | CA3182626A1 (https=) |
| MX (1) | MX2022016321A (https=) |
| WO (1) | WO2021257353A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230038526A (ko) | 2020-07-10 | 2023-03-20 | 머크 샤프 앤드 돔 엘엘씨 | 혈장 칼리크레인 억제제 |
| US20230416227A1 (en) * | 2020-09-10 | 2023-12-28 | Merck Sharp & Dohme Llc | Plasma kallikrein inhibitors |
| CN116120272A (zh) * | 2022-12-31 | 2023-05-16 | 淮北师范大学 | 一种合成咯菌腈中间体2,2-二氟-1,3-苯并二噁茂-4-甲醛的方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140378474A1 (en) * | 2012-01-27 | 2014-12-25 | Novartis Ag | 5-membered heteroarylcarboxamide derivatives as plasma kallikrein inhibitors |
| CN106257976B (zh) * | 2014-03-07 | 2021-02-02 | 拜奥克里斯特制药公司 | 人类血浆激肽释放酶抑制剂 |
| GB201421083D0 (en) | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | Enzyme inhibitors |
| JP6855477B2 (ja) | 2015-10-27 | 2021-04-07 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 血漿カリクレイン阻害薬としてのヘテロアリールカルボキサミド誘導体 |
| IL263235B (en) | 2016-05-31 | 2022-07-01 | Kalvista Pharmaceuticals Ltd | History of pyrazoles as plasma kallikrein inhibitors |
| WO2019012003A1 (en) | 2017-07-13 | 2019-01-17 | Syngenta Participations Ag | MICROBIOCIDE OXADIAZOLE DERIVATIVES |
-
2021
- 2021-06-10 JP JP2022577145A patent/JP7776453B2/ja active Active
- 2021-06-10 CA CA3182626A patent/CA3182626A1/en active Pending
- 2021-06-10 CN CN202180050323.XA patent/CN115989224B/zh active Active
- 2021-06-10 KR KR1020237001243A patent/KR102931248B1/ko active Active
- 2021-06-10 US US18/007,787 patent/US12459927B2/en active Active
- 2021-06-10 EP EP21826734.2A patent/EP4164634A4/en active Pending
- 2021-06-10 AU AU2021292449A patent/AU2021292449A1/en active Pending
- 2021-06-10 MX MX2022016321A patent/MX2022016321A/es unknown
- 2021-06-10 WO PCT/US2021/036706 patent/WO2021257353A1/en not_active Ceased
- 2021-06-10 BR BR112022025528A patent/BR112022025528A2/pt unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2020121150A (ru) | Твердые формы ингибитора калликреина плазмы и его солей | |
| JP2012530703A5 (https=) | ||
| JP2021169499A5 (https=) | ||
| JP2021523221A5 (https=) | ||
| JP2018535963A5 (https=) | ||
| RU2016133980A (ru) | Композиции и способы для лечения заболеваний глаз | |
| JP2019517487A5 (https=) | ||
| JP2017505794A5 (https=) | ||
| JP2019510787A5 (https=) | ||
| JP2017502033A5 (https=) | ||
| RU2016108753A (ru) | Ингибиторы ферментов | |
| CA3025720A1 (en) | Polymorphs of n-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-3-(methoxymethyl)-1 -({4-[2-oxopyridin-1 -yl)methyl]phenyl} methyl) pyrazole -4-carboxamide as kallikrein inhibitors | |
| RU2017112522A (ru) | Новые соединения и композиции для ингибирования nampt | |
| JP2009544618A5 (https=) | ||
| JP2021527125A5 (https=) | ||
| JP7844513B2 (ja) | 疾患の処置のためのベータ－ラクタム誘導体 | |
| JP2016535042A (ja) | ２−ベンジル−ベンゾイミダゾール補体因子ｂ阻害剤およびその使用 | |
| JPH04503672A (ja) | 放射線増感剤としての新規なナフタレンスルホンアミド | |
| JP2020527173A5 (https=) | ||
| RU2017110211A (ru) | ИНГИБИТОРЫ α-АМИНО-β-КАРБОКСИМУКОНАТ-ε-СЕМИАЛЬДЕГИД-ДЕКАРБОКСИЛАЗЫ | |
| JP2021535112A5 (https=) | ||
| JP2019505529A5 (https=) | ||
| JPWO2022251502A5 (https=) | ||
| JP2024003167A5 (https=) | ||
| US20100087436A1 (en) | Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection |